Overview

A Study of Baricitinib (LY3009104) in Participants With COVID-19

Status:
Completed
Trial end date:
2021-06-10
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company